A group of researcher announced that a clot-busting drug called Alteplase, which is a fantastic performer in dealing with heart attacks and non-bleeding strokes, has good records of declining post-stroke disability. This drug also reduces mortality in patients with bleeding stroke. After conducting thorough investigation in a clinical trial, researchers found this information. Researchers announced this discovery on the 2016th international stroke conference.
This drug works as a tissue plasminogen activator or tPA, and lightens blood cells those amalgamate in the brains of patients with intraventricular hemorrhage. This drug also decreases death rates by 10 percent .The group of Researcher reported at the 2016 International Stroke Conference that this drug is solely responsible of doubling possibility of utilitarian recovery after going through intraventricular hemorrhage.
Intraventricular hemorrhage is a lethal type of stroke. This type of stoke forces amalgamation of blood cells and clotting in the patient’s brain. Intraventricular hemorrhage accounts for 15 percent of all strokes. However, Intraventricular hemorage is solely responsible for 40 percent of stroke deaths. More than 60 to 80 percent of the patients of intraventricular hemorrhage do not last and more than 90 percent of those who last the stroke, looses most of their former physical functionality .Dr. Issam Awad, a professor of surgery at the University of Chicago stated “For many patients, this approach can significantly reduce disability after a stroke, and can be the difference between going home instead of going to a nursing home,”.
Researchers investigated cases of 500 patients from different part of the world with intraventricular hemorrhage. The research team treated them with tPA and saline using a brain catheter. Those patients were also looked up for five years. The death rate in patients declined by 10 percents after tPA was induced. The death rate was also one third lower compared with the saline group’s death rate.
The group of researchers explained that around 18 percents patients with bigger blood clot improved their condition after receiving tPA compared to those who received saline. Researchers also stated that more than 79.8 percent of patients who were given tPA had experienced 80 percent of clot removal. Dr. Issam Awad stated “When we entered into the trial, we knew very little about how this therapy ought to be used, in whom it should be used, and whether it was safe, We now have clear data on how best to implement the procedure, and for at least a group of patients, we know it can nearly double the likelihood of a favorable outcome.”